Lewy Body Dementia clinical trials at University of California Health

6 in progress, 0 open to eligible people

Showing trials for

  • Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    Sorry, not yet accepting patients

    The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.

    at UCSD

  • Parkinson's And Zoledronic Acid

    Sorry, in progress, not accepting new patients

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    at UC Davis UC Irvine UCLA UCSF

  • Diagnostic Test for Dementia With Lewy Bodies

    Sorry, in progress, not accepting new patients

    The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

    at UCSD

  • Environmental and Reproductive Health Risk for Lewy Body Dementia

    Sorry, in progress, not accepting new patients

    The goal of this survey study is to identify environmental, occupational and reproductive health risk factors for Lewy body dementia, which includes Parkinson's disease dementia and dementia with Lewy bodies. Participants will complete a one-time survey online or over the phone that includes questions on environmental, occupational factors they may have been exposed to and on medical history including reproductive health. Researchers will then compare the responses of people with Lewy body dementia and people without Parkinson's or memory/thinking problems to see which factors play a role in Lewy body dementia. Identifying risk factors can guide future treatment efforts and provide more insight to this dementia.

    at UCSD

  • North American Prodromal Synucleinopathy Consortium

    Sorry, accepting new patients by invitation only

    This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

  • North American Prodromal Synucleinopathy Consortium Stage 2

    Sorry, accepting new patients by invitation only

    This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

Our lead scientists for Lewy Body Dementia research studies include .

Last updated: